日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study

抗PD-1抗体联合P-GEMOX化疗与P-GEMOX化疗联合或不联合自体干细胞移植治疗既往未接受治疗的晚期自然杀伤/T细胞淋巴瘤:一项回顾性队列研究

Zou, Qihua; Cao, Yi; Wang, Liang; Li, Wuping; Yin, Qingsong; Wu, Yudan; Jing, Hongmei; Peng, Zhigang; Sun, Xiuhua; Rao, Jun; Chen, Ying; Zhang, Hongyu; Zeng, Dongfeng; Li, Bingzong; Zhao, Ying; Zhang, Xudong; Zhang, Yuchen; Gao, Yan; Bai, Bing; Xia, Yi; Fang, Yu; Chen, Zouxiang; Nie, Man; Fang, Xiaojie; Bai, Shenrui; Huang, Huiqiang; Cai, Qingqing; Cai, Jun

A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction

修订后的自然杀伤/T细胞淋巴瘤分期系统,纳入了颅底侵犯和鼻/非鼻亚型区分。

Cao, Yi; Zhang, Yuchen; Wang, Liang; Song, Yongping; Qi, Shunan; Cai, Peiqiang; Tao, Rong; Li, Zhihua; Shuang, Yuerong; Yin, Qingsong; Peng, Zhigang; Zhong, Liye; Sun, Xiuhua; Zhang, Hongyu; Zhao, Ying; Jing, Hongmei; Li, Bingzong; Zou, Qihua; Huang, Huiqiang; Gao, Yan; Xia, Yi; Nie, Man; Fang, Xiaojie; Gao, Xinna; Bai, Shenrui; Cai, Jun; Cai, Qingqing

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Finotonlimab(PD-1抑制剂)联合贝伐单抗(贝伐单抗生物类似药)作为晚期肝细胞癌的一线治疗方案:一项随机2/3期试验

Zhao, Chuanhua; Zhang, Yanqiao; Wang, Gang; Zheng, Jinfang; Chen, Weiqing; Lu, Zheng; Zhuang, Li; Gu, Shanzhi; Han, Lei; Zheng, Zhendong; Yu, Zujiang; Yang, Yongsheng; Sun, Hongmei; Wei, Xiaoyong; Cheng, Ying; Lin, Hailan; Zhu, Bo; Wu, Guicheng; Lei, Kaijian; Wang, Wei; Wang, Yuwen; Chen, Kehe; Xu, Ximing; Zheng, Cuiping; Bi, Yanzhi; Ding, Sijuan; Zhang, Jingdong; Li, Wei; Liu, Hailong; Wang, Jun; Liu, Xianling; Du, Yangfeng; Cai, Lianming; Wang, Jingran; Luo, Zhanxiong; Xing, Baocai; Shen, Jie; Yang, Lin; Wu, Jianbing; Jiang, Ou; Peng, Zhigang; Liu, Xiuli; Cao, Bangwei; Shen, Liangfang; Xu, Aibing; Li, Aimin; Chen, Shaojun; Fu, Ting; Chen, Jian; Jin, Chuan; Zhang, Lei; Lv, Jun; Zhang, Chengwu; Zhang, Xiaoman; Wang, Yu; Su, Huo; Zhou, Qiang; Gai, Wenlin; Xie, Liangzhi; Xu, Jianming

A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma

一项针对复发和/或难治性外周T细胞淋巴瘤患者的HH2853治疗的多中心、开放标签、单臂Ib期临床试验

Hong, Huangming; Chen, Zegeng; Zhang, Mingzhi; Peng, Zhigang; Shen, Jianzhen; Shuang, Yuerong; Zhou, Hui; Guo, Hongqiang; Huang, He; Li, Fei; Qian, Zhengzi; Liu, Lihong; Wang, Liang; Yang, Wei; Zhang, Liling; He, Pengcheng; Qian, Shen; Li, Fugen; Li, Meng; Lin, Tongyu

Regulation of cellular senescence in tumor progression and therapeutic targeting: mechanisms and pathways

肿瘤进展中细胞衰老的调控及治疗靶向:机制和通路

Liu, Bowei; Peng, Zhigang; Zhang, Hao; Zhang, Nan; Liu, Zaoqu; Xia, Zhiwei; Huang, Shaorong; Luo, Peng; Cheng, Quan

Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial

Tifcemalimab 单药治疗或联合 toripalimab 治疗复发/难治性淋巴瘤患者:一项 I 期试验

Song, Yuqin; Ma, Jun; Zhang, Huilai; Xie, Yan; Peng, Zhigang; Shuang, Yuerong; Li, Fei; Li, Yufu; Yang, Haiyan; Zou, Liqun; Sun, Xiuhua; Zhao, Weili; Huang, Wenrong; Huang, Yunhong; Zhou, Hui; Wang, Yifan; Wang, Weiwei; Xu, Jing; Deng, Rong; Meng, Qin; Zhu, Jun

Cytosolic TOP3α facilitates mitochondrial DNA sensing by cGAS.

胞质 TOP3α 促进 cGAS 对线粒体 DNA 的感知。

Cai Dongjing, Chen Cheng, Meekrathok Piyanat, Zeng Weiqian, Wang Zheng, Peng Zhigang, Mo Yunan, Xu Xia, Wang Junling, Qiu Jian

Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial

脂质体米托蒽醌单药治疗复发或难治性成熟T细胞和自然杀伤细胞肿瘤患者:一项II期、多中心、开放标签、单臂试验

Gao, Yan; Huang, Yunhong; Zhang, Qingyuan; Yang, Haiyan; Li, Yufu; Li, Yan; Zhou, Min; Yang, Runxiang; Xu, Bing; Liu, Lihong; Yang, Yu; Peng, Zhigang; Yu, Ding; Zhou, Hui; Zhang, Rongyan; Zhang, Huilai; Qi, Junyuan; Xi, Yaming; Xing, Xiaojing; Wang, Zhao; Jing, Hongmei; Shuang, Yuerong; Zhang, Xiaohong; Ma, Liping; Jin, Hongyan; Lin, Li'e; Li, Chunlei; Xue, Jianfei; Liu, Yanping; Yuan, Jing; Huang, Huiqiang

Efficacy of brentuximab vedotin combined with sintilimab in relapsed/refractory DLBCL patient with secondary hemophagocytic syndrome: a case report and literature review

布伦妥昔单抗联合信迪利单抗治疗复发/难治性弥漫性大B细胞淋巴瘤合并继发性噬血细胞综合征患者的疗效:病例报告及文献综述

Cheng, Siyu; Wu, Huihong; Bao, Wenguang; Peng, Zhigang; Huang, Fengxiang; Zhou, Shengsheng; Mo, Qinli; Li, Ye; Bin, Yehong; Lan, Dong; Yang, Haiyan

Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study

中国1031例外周T细胞淋巴瘤患者的临床特征、治疗模式和生存结局:一项多中心真实世界研究

Huang, Ling; Yang, Yong; Zhao, Zhenyu; Zhou, Shengsheng; Wu, Jingsong; Wang, Ning; Zhang, Fen; Shi, Keqian; Li, ChengPing; Wei, Xiaolei; Zhang, Hongyu; Lin, Yun; Li, Guowei; Zhou, Hui; Guo, Hanguo; Jiang, Xinmiao; Wei, Xiaojuan; Chen, Feili; Liu, Sichu; Lin, Caidi; Liang, Zhanli; Huang, Yilan; Pan, Lu; Yang, Hui; Jiang, Yirong; Wu, Yudan; Cheng, Shuqin; Yang, Huifang; Zheng, Xiaoqiang; Chen, Xinggui; Li, Xiaoliang; Huang, GuiNian; Zhou, Jihao; Peng, Zhigang; Lin, Li-E; Liu, Tingbo; Li, Wenyu